Navigation Links
Pilot Testing Phase Ends; Expansion Of Sales Force Begins
Date:4/13/2010

PreEmptive Meds, Inc., a plant-based pharma-nutraceutical company, which promotes its proprietary, all-natural formulations as evidence-based alternatives for the primary care physician, announces the completion of its pilot testing phase and its initiation of sales force expansion.

Whitehouse Station, NJ/Las Vegas, NV (PRWEB) April 14, 2010 -- PreEmptive Meds, Inc., a plant-based pharma-nutraceutical company, which promotes its proprietary, all-natural formulations as evidence-based alternatives for the primary care physician, announces the completion of its pilot testing phase and its initiation of sales force expansion.

Over the past three years, the company has been promoting, on a pilot test basis, its current product line with experienced pharmaceutical-trained sales associates to physicians in selected pockets of northern New Jersey, New York City and Long Island, NY with favorable acceptance and patient outcomes. The Company has now expanded its sales effort to 16 sales associates and plans to continue its expansion to 30 sales associates by July 1st, 2010. The current sales effort is and will be focused up and down the east coast corridor from Massachusetts to Florida, and into Texas, Pennsylvania and Illinois. Expansion is planned to continue throughout 2011 with the goal to have a national sales effort within prominent high-density metropolitan Primary Care Physician areas across the country.

The Company currently promotes seven products: PreCrea® for pre-diabetes; PreLipid® and PreLipid Plus®, for lowering cholesterol naturally; PreMenora® and PreMenora®Plus, for relieving symptoms of perimenopause; and PreArthros™, and PreArthros™Plus for joint inflammation and pain, via a pharmaceutical style sales force. In addition, the Company has also developed a series of new formulations as viable all-natural alternatives for various chronic conditions, which it plans to launch over time once it has established a sufficient beachhead with its current product line with Primary Care Physicians.

Chuck Blitzer, the Company’s Chief Executive Officer stated, “We are extremely pleased with the results from our pilot testing program (which reached over 1,500 physicians and over 200,000 patient experiences) and now, our effort to formally begin building a national sales organization. Our sales associates are highly proven individuals from the pharmaceutical industry and average over 12 years of direct selling experience within the Primary Care Physician community, the largest physician audience in the country.

Our products are recommended by thousands of physicians as:

1) First-line therapy for pre-disease states, where no prescription drugs are approved,
2) An alternative for patients who are intolerant to prescription drugs or refuse to go onto a prescription drug, and
3) Additive therapy to a given prescription drug where the desired therapeutic effect of such drug has not been achieved and the physician is inclined not to increase dose.”

The Company’s financial position is sound and it hasn’t needed to raise capital since its last round of financing in 2008. It is debt free and believes it is on track to break-even by years’ end.

Dr. Joe Fenn, President and Chief Medical Officer stated “From our pilot program we learned how to promote our products effectively to Primary Care Physicians, and in every sales territory we now expand to we have doctors eager to hear our message and adopt our products as alternatives for their patients. We have also established the efficacy and safety of our products in tens of thousands of patients. ”

PreEmptive Meds, Inc., is a pre-disease focused, plant-based pharma-nutraceutical company promoting its proprietary branded products directly to the Primary Care Physician community.

###

Read the full story at http://www.prweb.com/releases/preemptivemeds/salesteam/prweb3865604.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. HealthEquity Partners with State of Utah to Launch Pilot of Utah Health Exchange
2. Howard Leights New Pilot Push-in Ear Plug Delivers Occupational Hearing Protection with Innovative, Hybrid Design
3. Acumen Fund Announces Ripple Effect Pilot Projects In Kenya To Identify Innovative Solutions To Water Challenges
4. Edifecs Testifies Before NCVHS Standards Subcommittee Regarding HIPAA 5010 and ICD-10 Testing
5. Doctors and Scientists Create New Society to Promote Non-Animal Toxicology Testing Methods
6. The Institute of Women's Health of North America to Offer Free Chlamydia Testing at All Affiliated Campuses – Dr. Abdul Rao
7. AXIOM Systems, Inc. Announces General Release of HIPAA 5010 Testing Solutions
8. ANY LAB TEST NOW North Dallas Lowers Diabetes Testing to $89
9. Refinement of glaucoma testing, treatment expected from US, United Kingdom study
10. Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification
11. Statement from American Water Works Association on the Environmental Working Group's report on Tap Water Quality Testing and Violations
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Pilot Testing Phase Ends; Expansion Of Sales Force Begins
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will ... of Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention ... long been the gold standard for high-definition, in-ear earphones. This classic earphone has ...
(Date:1/17/2017)... ... 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting provider ... in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted that ... , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug Administration ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons ... to primary eye care practitioners on the latest breakthroughs in the prevention, diagnosis ... Continuing Education Symposium, according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive ...
(Date:1/17/2017)... ... 17, 2017 , ... Neil H. Greco Insurance Agency, a northern New Jersey ... region, is launching a charity drive to raise awareness of heart disease and promote ... in America, and is responsible for 1 in every 4 deaths at the national ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley ... double blind clinical study for its dental gel that shows significant reduction in plaque ... toothpaste containing triclosan. The study was conducted at the Beckman Laser Institute at UC ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Research Future published a Half Cooked Research Report on Endoscopy Devices ... 33.6 million during the period 2016 to 2022 from USD 28.7 ... ... examined as a swiftly growing market and expected to grow at ... in various regions.  The increasing growth in endoscopy procedures is influencing ...
(Date:1/17/2017)... KANSAS CITY, Mo. , Jan. ... (CHNC) has selected Velos and its flagship technology ... and multicenter initiatives. CHNC is a ... Neonatal Intensive Care Units at leading children,s hospitals ... consortium provides a benchmark of care and short-term ...
(Date:1/17/2017)...  Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is ... Inc. ("Anthera" or the "Company") (NASDAQ: ANTH ). ... the investigation by visiting the firm,s site: www.bgandg.com/anth .   ... its officers and/or directors have violated Sections 10(b) and 20(a) ... ...
Breaking Medicine Technology: